P-Glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity

Toxicology and Applied Pharmacology

Volumn 143, Issue 2, 1997, Pages 357-365

  Lankas, George R ^a   Cartwright, Mark E ^a   Umbenhauer, Diane ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABAMECTIN; AVERMECTIN; GLYCOPROTEIN P; IVERMECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG TISSUE LEVEL; FEMALE; IMMUNOHISTOCHEMISTRY; INTRAGASTRIC DRUG ADMINISTRATION; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEIN DEFICIENCY; STRAIN DIFFERENCE;

EID: 0030972417     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1996.8086     Document Type: Article

References (27)

1. Albers-Schonberg G., Arison B., Chabala J., Douglas A., Eskola P., Fisher M., Lusi A., Mrozik H., Smith J., Tolman R. Avermectins. Structure determination. J. Am. Chem. Soc. 103:1981;4216-4221.
2. Altuvia S., Stein W., Goldenberg S., Kane S., Pastan I., Gottesman M. Targeted disruption of the mousemdr1bmdr. J. Biol. Chem. 268:1993;27127-27132.
3. Arena J., Liu K., Paress P., Frazier E., Cully D., Mrozik H., Schaeffer J. The mechanism of action of avermectins inCaenorhabditis elegans: J. Parasitol. 81:1995;286-294.
4. Beck W., Cirtain M., Lefko J. Energy-dependent reduced drug binding as a mechanism of vinca alkaloid resistance in leukemic lymphoblasts. Mol. Pharmacol. 24:1983;485-492.
5. Beck W. The cell biology of multiple drug resistance. Biochem. Pharmacol. 36:1987;2879-2887.
6. Beck W. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. 1991;. p. 215-227.
7. Chen C., Chin J., Ueda K., Clark D., Pastan I., Gottesman M., Roninson I. Internal duplication and homology with bacterial transport proteins in themdr1. Cell. 47:1986;381-389.
8. Chin J., Soffir R., Noonan K., Choi K., Roninson I. Structure and expression of the humanMDR. Mol. Cell. Biol. 9:1989;3808-3820.
9. Chiu S., Lu A. Metabolism and tissue residues. Ivermectin and Abamectin. 1989;Springer-Verlag, New York. p. 131-143.
10. Cordon-Cardo C., O'Brien J., Casals D., Rittman-Grauer L., Biedler J., Melamed M., Bertino J. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA. 86:1989;695-698.
11. Costa J., Diazgranados J. Ivermectin for spasticity in spinal-cord injury. Lancet. 343:1994;739.
12. Croop J., Raymond M., Haber D., Devault A., Arceci R., Gros P., Housman D. The three mouse multidrug resistance (mdr. Mol. Cell. Biol. 9:1989;1346-1350.
13. Deuchars K., Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin. Oncol. 16:1989;156-165.
14. Endicott J., Juranka P., Sarangi F., Gerlach J., Deuchars K., Ling V. Simultaneous expression of two P-glycoprotein genes in drug sensitive Chinese hamster ovary cells. Mol. Cell. Biol. 7:1987;4075-4081.
15. Endicott J., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:1989;137-171.
16. Fisher M., Mrozik H. Chemistry. Campbell W. C. Ivermectin and Abamectin. 1989;131-143 Springer-Verlag, New York.
17. Gerlach H., Endicott J., Juranka P., Henderson G., Sarangi F., Deuchars K., Ling V. P-glycoprotein in human sarcoma: Evidence for multidrug resistance. J. Clin. Oncol. 5:1987;1452-1460.
18. Goldstein L., Galski H., Fojo A., Willingham M., Lai S., Gazdar A., Pirker R., Green A., Crist W., Brodeur G., Lieber M., Cossman J., Gottesman M., Pastan I. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81:1989;116-124.
19. Gottesman M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
20. Gros P., Croop J., Housman D. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell. 47:1986;371-380.
21. Laemmli U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
22. Lankas G., Gordon L. Toxicology. Campbell W. C. Ivermectin and Abamectin. 1989;131-143 Springer-Verlag, New York.
23. Lum B., Gosland M. MDR expression in normal tissues - Pharmacological implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. NA. 9:1995;319-336.
24. MECTIZAN Program Notes, Issue 12, 1994, MECTIZAN Donation Program, One Copenhill, Atlanta, GA.
25. Schinkel A., Smit J., van Tellingen O., Beijnen J., Wagenaar E., van Deemter L., Mol C., van der Valk M., Robanus-Maandag E., Riele H., Berns A., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
26. Schinkel A., Wagenaar E., van Deemter L., Mol C., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1995;1698-1705.
27. Thiebaut F., Tsuruo T., Hamada H., Gottesman M., Pastan I., Willingham M. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc. Natl. Acad. Sci. USA. 84:1989;7735-7738.